These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16209572)

  • 1. A comparison of cyclohexanone and tetrahydro-4H-thiopyran-4-one 1,1-dioxide as pharmacophores for the design of peptide-based inhibitors of the serine protease plasmin.
    Xue F; Seto CT
    J Org Chem; 2005 Oct; 70(21):8309-21. PubMed ID: 16209572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective inhibitors of the serine protease plasmin: probing the S3 and S3' subsites using a combinatorial library.
    Xue F; Seto CT
    J Med Chem; 2005 Nov; 48(22):6908-17. PubMed ID: 16250649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrocyclic inhibitors for the serine protease plasmin.
    Xue F; Seto CT
    J Enzyme Inhib Med Chem; 2009 Jun; 24(3):779-94. PubMed ID: 18825554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-Heterocyclohexanone-based inhibitors of the serine protease plasmin.
    Sanders TC; Seto CT
    J Med Chem; 1999 Jul; 42(15):2969-76. PubMed ID: 10425106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasmin substrate binding site cooperativity guides the design of potent peptide aldehyde inhibitors.
    Swedberg JE; Harris JM
    Biochemistry; 2011 Oct; 50(39):8454-62. PubMed ID: 21877690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity studies of cyclic ketone inhibitors of the serine protease plasmin: design, synthesis, and biological activity.
    Xue F; Seto CT
    Bioorg Med Chem; 2006 Dec; 14(24):8467-87. PubMed ID: 16971130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of Cyclic Plasmin Inhibitors: From Benzamidines to Benzylamines.
    Hinkes S; Wuttke A; Saupe SM; Ivanova T; Wagner S; Knörlein A; Heine A; Klebe G; Steinmetzer T
    J Med Chem; 2016 Jul; 59(13):6370-86. PubMed ID: 27280436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrrolopyrimidine-inhibitors with hydantoin moiety as spacer can explore P4/S4 interaction on plasmin.
    Teno N; Gohda K; Wanaka K; Tsuda Y; Sueda T; Yamashita Y; Otsubo T
    Bioorg Med Chem; 2014 Apr; 22(7):2339-52. PubMed ID: 24613052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active site-directed plasmin inhibitors: Extension on the P2 residue.
    Hidaka K; Gohda K; Teno N; Wanaka K; Tsuda Y
    Bioorg Med Chem; 2016 Feb; 24(4):545-53. PubMed ID: 26732532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors of plasmin that extend into both the S and S' binding sites: cooperative interactions between S1 and S2.
    Abato P; Yuen CM; Cubanski JY; Seto CT
    J Org Chem; 2002 Feb; 67(4):1184-91. PubMed ID: 11846661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural and engineered plasmin inhibitors: applications and design strategies.
    Swedberg JE; Harris JM
    Chembiochem; 2012 Feb; 13(3):336-48. PubMed ID: 22238174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of potent and selective plasmin and plasma kallikrein inhibitors and studies on the structure-activity relationship.
    Okada Y; Tsuda Y; Tada M; Wanaka K; Okamoto U; Hijikata-Okunomiya A; Okamoto S
    Chem Pharm Bull (Tokyo); 2000 Dec; 48(12):1964-72. PubMed ID: 11145152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular cloning and antifibrinolytic activity of a serine protease inhibitor from bumblebee (Bombus terrestris) venom.
    Qiu Y; Lee KS; Choo YM; Kong D; Yoon HJ; Jin BR
    Toxicon; 2013 Mar; 63():1-6. PubMed ID: 23164714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel type of plasmin inhibitors: providing insight into P4 moiety and alternative scaffold to pyrrolopyrimidine.
    Teno N; Gohda K; Wanaka K; Tsuda Y; Akagawa M; Akiduki E; Araki M; Masuda A; Otsubo T; Yamashita Y
    Bioorg Med Chem; 2015 Jul; 23(13):3696-704. PubMed ID: 25921265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of new cyclic plasmin inhibitors with excellent potency and selectivity.
    Saupe SM; Leubner S; Betz M; Klebe G; Steinmetzer T
    J Med Chem; 2013 Feb; 56(3):820-31. PubMed ID: 23294255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new strategy for the development of highly potent and selective plasmin inhibitors.
    Saupe SM; Steinmetzer T
    J Med Chem; 2012 Feb; 55(3):1171-80. PubMed ID: 22276953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study on the inhibition of plasmin and delta-plasmin via benzamidine derivatives.
    Alves NJ; Kline JA
    Biochem Biophys Res Commun; 2015 Feb; 457(3):358-62. PubMed ID: 25576865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances on plasmin inhibitors for the treatment of fibrinolysis-related disorders.
    Al-Horani RA; Desai UR
    Med Res Rev; 2014 Nov; 34(6):1168-216. PubMed ID: 24659483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of active center-directed peptide inhibitors of plasmin.
    Okada Y; Tsuda Y; Teno N; Wanaka K; Bohgaki M; Hijikata-Okunomiya A; Naito T; Okamoto S
    Chem Pharm Bull (Tokyo); 1988 Apr; 36(4):1289-97. PubMed ID: 2970896
    [No Abstract]   [Full Text] [Related]  

  • 20. Synthesis and activity of N epsilon-aminocaproyl-L-norleucine derivatives.
    Midura-Nowaczek K; Bruzgo I; Roszkowska-Jakimiec W; Worowski K
    Acta Pol Pharm; 1996; 53(3):221-3. PubMed ID: 8960292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.